Eravacycline Dihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Eravacycline Dihydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
23
Registered trials
14
Result records
9
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Eravacycline Dihydrochloride can convert its Small molecule drug profile and 30S subunit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Eravacycline Dihydrochloride (query alias: eravacycline) |
|---|---|
| Modality / target | Small molecule drug; 30S subunit; 30S subunit inhibitors |
| Highest global status | Approved |
| Originator | Tetraphase Pharmaceuticals (Bermuda) Ltd. |
| Active developers | Everest Medicines (Singapore) Pte Ltd., Genting Pharmaceutical (Suzhou Co Ltd., PAION AG |
The MCP disease footprint includes Complicated intra-abdominal infection, Community-acquired bacterial pneumonia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06440304 | Phase 4 | Recruiting | 108 | Negativisation |
| ChiCTR2400087137 | Phase 4 | Notyet recruiting | 4 | Drug concentration in plasma |
| NCT06794541 | Phase 2 | Recruiting | 35 | Proportion of patients with Adverse Events (AEs) from the first dose of any amount of eravacycline |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD
Phase 1; n=83; evaluation: Positive. Reported fields: ELF distribution ratio = 8.26 mg/L ( 6.8 - 9.8)
“依拉环素临床应用综合评价项目”终期报告发布：整体治疗有效率90.1%，证实依拉环素良好疗效与安全性
N/A; n=3369; evaluation: 积极. Reported fields: 整体有效率 = 90.1 %
The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis
Not Applicable; n=9372; evaluation: Positive. Reported fields: Microbiological response rate: RR = 0.82(95.0% CI, 0.65 - 0.99); Microbiological response rate: RR = 0.82(95.0% CI, 0.65 - 0.99)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Eravacycline Dihydrochloride addresses Complicated intra-abdominal infection, Community-acquired bacterial pneumonia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 9 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-04-19 | SPH Keyuan Xinhua Pharmaceutical to sign MoU with Everest Medicines for commercialization of Xerava in mainland China, targeting complicated intra-abdominal infections. | Approved | Financial terms not disclosed |
| 2022-11-16 | PAION AG enters partnership with Viatris and expands sales activities in Europe | Approved | Financial terms not disclosed |
| 2022-08-10 | Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
